Dynamic Advisor Solutions LLC Sells 15,282 Shares of Abbott Laboratories $ABT

Dynamic Advisor Solutions LLC decreased its stake in Abbott Laboratories (NYSE:ABT) by 33.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,885 shares of the healthcare product maker’s stock after selling 15,282 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Abbott Laboratories were worth $3,744,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ABT. TABR Capital Management LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at $7,360,000. Tompkins Financial Corp increased its holdings in shares of Abbott Laboratories by 0.5% during the 4th quarter. Tompkins Financial Corp now owns 103,131 shares of the healthcare product maker’s stock worth $12,921,000 after purchasing an additional 532 shares during the period. Gradient Investments LLC raised its position in shares of Abbott Laboratories by 15.7% during the fourth quarter. Gradient Investments LLC now owns 346,541 shares of the healthcare product maker’s stock valued at $43,418,000 after buying an additional 47,135 shares during the last quarter. Regent Peak Wealth Advisors LLC raised its position in shares of Abbott Laboratories by 4.4% during the fourth quarter. Regent Peak Wealth Advisors LLC now owns 5,393 shares of the healthcare product maker’s stock valued at $676,000 after buying an additional 226 shares during the last quarter. Finally, Armstrong Advisory Group Inc. lifted its stake in shares of Abbott Laboratories by 12.4% in the fourth quarter. Armstrong Advisory Group Inc. now owns 4,389 shares of the healthcare product maker’s stock valued at $550,000 after buying an additional 483 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays lowered their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Evercore reduced their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Royal Bank Of Canada lowered their price objective on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Sanford C. Bernstein cut their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Argus reduced their target price on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $136.16.

Abbott Laboratories Stock Down 0.6%

Shares of ABT opened at $104.87 on Tuesday. Abbott Laboratories has a 12 month low of $104.10 and a 12 month high of $139.06. The stock has a market cap of $182.65 billion, a price-to-earnings ratio of 28.19, a P/E/G ratio of 1.68 and a beta of 0.74. The company has a 50-day moving average price of $112.36 and a two-hundred day moving average price of $122.77. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Activity at Abbott Laboratories

In related news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president directly owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 3,055 shares of company stock valued at $353,097. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.